A prospective cross-over study examining the use of 5% dextrose in people receiving haemodialysis

Background: Intradialytic hypotension is a frequent haemodialysis complication. Aim: This multicentre, prospective, cross-over interventional study aims to compare the effectiveness of 5% Dextrose for priming, reinfusion and treatment of intravascular volume depletion symptoms against 0.9% normal saline in nondiabetic people receiving haemodialysis therapy. The primary objective is to reduce interdialytic weight gain thereby preventing rapid ultrafiltration during haemodialysis. The secondary objective is to minimise symptoms of intravascular volume depletion during haemodialysis treatments. Methods: The study population will include adult haemodialysis patients who are able to provide informed consent and who have been receiving haemodialysis for a minimum of 6 months with a permanent vascular access. Fifty participants will be recruited. Participants will continue to receive 0.9 percent Normal Saline for priming, reinfusion and treatment of symptoms during haemodialysis treatments for 3 months. Participants will then cross-over using 5% Dextrose for the following 6 months. The measurement of treatment effects includes interdialytic weight gain, vital signs, symptoms of intravascular volume depletion, blood volume monitoring and blood sugar levels. Adverse events will be tracked and monitored. This study has been designed to provide evidence and assist renal clinicians in determining the optimal strategy for preventing the need for rapid ultrafiltration during haemodialysis therapy.